证券代码：000790 证券简称：泰合健康 编号：2016-01 成都泰合健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国泰君安 夏玮祥 | | | 人员姓名 | | | | 时间 | 2016.11.21 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 叶静、刘渝灿 | | | 员姓名 | | | | 投资者关系活动 | | 现场会议座谈了解公司基本情况，未提供书面资料。 | | 主要内容介绍 | | 一、现有业务如何规划？未来公司发展重心是什么？ | | | | 公司坚持以现代中药为核心 ...

证券代码：000790 证券简称：华神科技 编号：2022-001 成都华神科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | ■ 现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 民生证券（宋丽莹）、尺度财金（张仟） | | 时间 | 2022 年 1 月 13 日上午 | 10:00 | | | | 地点 成都华神科技集团股份有限公司四楼会议室 | | 上市公司接待人 | | 常务副总裁孙继林先生、财务负责人李俊先生、董事 ...

证券代码：000790 证券简称：华神科技 成都华神科技集团股份有限公司 投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |------------------|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐ 分析师会议 | | 投资者关系活动类 | ☐ 媒体采访 | ☐ 业绩说明会 | | 别 | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 | | | | 其他（电话会议） | | | 活动参与人员 | | 深圳铭翼投资管理有限公司（陈轩宇）、方洲基金管理有限公司（叶 辰）、个人投资者（郑紫玲）、广州铠泓投资咨询有 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥199,302,734.03, a decrease of 7.25% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥8,566,574.03, down 15.03% year-on-year[4] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥14,593,514.91, an increase of 40.49% compared to the previous year[4] - The basic earnings per share for Q3 2022 was ¥0.0137, a decrease of 16.46% year-on-year[4] - The net profit for Q3 2022 was CNY 22,599,592.44, a decrease of 27.5% compared to CNY 31,156,008.87 in Q3 2021[26] - Operating profit for Q3 2022 was CNY 27,193,306.63, down 30.6% from CNY 39,151,620.99 in the same period last year[26] - Total revenue from operating activities was CNY 600,483,424.39, an increase of 10.4% compared to CNY 543,949,664.38 in Q3 2021[29] - Basic and diluted earnings per share for Q3 2022 were CNY 0.0415, down from CNY 0.0566 in Q3 2021[26] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥1,485,607,366.30, reflecting a 9.95% increase from the end of the previous year[4] - The company's inventory increased by 53.39% to ¥134,595,409.09, primarily due to the acquisition of a subsidiary[10] - The long-term equity investments increased by 100% to ¥56,595,111.01, attributed to new investments in the Shandong Lingkai project[10] - The goodwill on the balance sheet reached ¥57,599,644.30, resulting from the premium paid in the acquisition of a subsidiary[10] - Total assets as of September 30, 2022, were CNY 1,485,607,366.30, compared to CNY 1,351,112,420.20 at the beginning of the year, reflecting an increase of 9.9%[23] - Total liabilities increased to CNY 508,824,114.93 from CNY 369,676,411.67, representing a rise of 37.6%[23] - Long-term borrowings reached ¥99,886,000.00, marking a 100% increase as a result of new bank financing[11] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥53,666,005.29, a significant improvement of 175.40% compared to the same period last year[4] - Cash received from operating activities decreased by 44.66% to ¥20,589,513.90, mainly due to reduced performance guarantees and other deposits[15] - Cash paid for the acquisition of fixed assets increased by 34.97% to ¥142,934,183.27, reflecting higher asset purchases[15] - The company secured bank loans totaling ¥200,000,000.00, a 1233.33% increase compared to ¥15,000,000.00 in the previous period[15] - Financing activities generated a net cash inflow of CNY 112,587,254.38, compared to CNY 20,762,167.16 in the same period last year[30] Expenses - R&D expenses increased by 31.68% to ¥17,824,086.28 due to higher investment in research and development[13] - Financial expenses rose by 190.08% to ¥1,823,182.55 primarily due to increased interest expenses from bank loans[13] - Selling expenses for Q3 2022 were CNY 137,717,051.81, a decrease of 14.2% from CNY 160,543,277.28 in Q3 2021[26] - The company incurred a financial expense of CNY 1,823,182.55, compared to a financial income of CNY 2,024,049.06 in the previous year[26] Shareholder Equity - The company's minority shareholders' equity rose by 51.36% to ¥7,479,165.46, driven by capital contributions from minority shareholders[11] - The company's equity attributable to shareholders decreased to CNY 969,304,085.91 from CNY 976,494,790.70, a decline of 0.9%[23] Strategic Initiatives - The company plans to invest up to ¥200,000,000.00 in Shanghai Lingkai Pharmaceutical Technology Co., acquiring a 5.7143% stake to enhance collaboration in the CDMO industry[18] - The company adjusted its 2021 restricted stock incentive plan to align with the current operating environment, ensuring better motivation and stability for the team[19]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 407,389,669.31, representing a 20.59% increase compared to CNY 337,822,043.33 in the same period last year[21]. - The net profit attributable to shareholders decreased by 23.09% to CNY 17,369,678.22 from CNY 22,583,211.17 in the previous year[21]. - The net profit after deducting non-recurring gains and losses fell by 42.83% to CNY 15,947,634.58 compared to CNY 27,892,749.03 in the same period last year[21]. - The basic earnings per share decreased by 24.04% to CNY 0.0278 from CNY 0.0366 in the same period last year[21]. - The weighted average return on net assets was 1.80%, down from 2.31% in the previous year[21]. - The company achieved a total revenue of 407.39 million yuan, representing a year-on-year growth of 20.59%[36]. - The net profit attributable to shareholders was 17.37 million yuan, a decline of 23.09% year-on-year, largely due to decreased sales in the pharmaceutical sector[37]. - The company reported a net profit margin improvement, with undistributed profits rising from CNY 182,259,993.72 to CNY 199,629,671.94, an increase of 9.5%[139]. - The net profit for the first half of 2022 was CNY 15,271,333.98, down 32.8% from CNY 22,737,455.22 in the same period of 2021[146]. - The operating profit for the first half of 2022 was CNY 19,004,077.48, a decline of 31.6% from CNY 27,844,729.92 in the first half of 2021[145]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to CNY 37,811,459.99, a 178.70% increase from a negative CNY 48,044,082.93 in the previous year[21]. - Cash inflow from operating activities was CNY 390,256,922.38 in the first half of 2022, compared to CNY 368,152,305.12 in the same period of 2021[150]. - Total cash outflow from investment activities reached ¥205,371,091.69, resulting in a net cash flow from investment activities of -¥200,891,423.69, compared to -¥99,244,742.63 in the previous year[152]. - Cash inflow from financing activities amounted to ¥79,170,000.00, while cash outflow totaled ¥64,479,701.63, leading to a net cash flow from financing activities of ¥14,690,298.37, up from ¥956,394.36 in 2021[152]. - The total cash and cash equivalents at the end of the period were ¥125,559,704.08, down from ¥232,839,826.61 at the end of the first half of 2021[152]. Business Segments and Operations - The pharmaceutical business revenue was 171.62 million yuan, a decrease of 30.08% year-on-year, primarily due to the impact of COVID-19 on major sales regions[36]. - The steel structure business saw a revenue increase of 76.94%, reaching 149.52 million yuan, driven by enhanced team incentives and resource integration[36]. - The newly acquired blue light mineral water beverage business contributed an additional revenue of 73.36 million yuan[36]. - The health industry segment saw a remarkable revenue increase of 2,354.00%, reaching CNY 71,086,909.03, compared to CNY 2,896,773.28 in the same period last year[47]. - The company is expanding its health product offerings by acquiring mineral water resources to diversify its business and reduce risks associated with the pandemic[72]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,406,100,454.29, up 4.07% from CNY 1,351,112,420.20 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 0.98% to CNY 966,940,039.73 from CNY 976,494,790.70 at the end of the previous year[21]. - Current liabilities increased to CNY 377,130,317.46, compared to CNY 327,550,537.98, marking a rise of 15.1%[139]. - Non-current liabilities totaled CNY 60,157,146.38, up from CNY 42,125,873.69, indicating a significant increase of 42.8%[139]. - The total liabilities at the end of the period were CNY 1,872,950, reflecting the company's leverage position[162]. Corporate Governance and Shareholder Relations - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has maintained its board and management personnel without changes during the reporting period, ensuring stability in governance[78]. - The company has a systematic approach to environmental monitoring, including third-party assessments of wastewater and air emissions every six months[88]. - The company has maintained a strong commitment to shareholder rights, ensuring timely and accurate information disclosure and facilitating shareholder participation in decision-making processes[91]. - Employee rights are prioritized, with compliance to labor laws, timely salary payments, and regular health checks to ensure a safe working environment[92]. Research and Development - The company is focusing on the development of new products based on existing advantages in therapeutic areas, particularly for its core products[33]. - The company aims to enhance its R&D capabilities by collaborating with domestic and international research institutions to adapt to changing market demands and improve product acceptance[73]. - Research and development expenses increased to CNY 13,364,976.44 in the first half of 2022, up 36.5% from CNY 9,818,160.05 in the first half of 2021[145]. Environmental and Social Responsibility - The company has achieved compliance with environmental standards, with all major pollutants from wastewater and exhaust gases meeting regulatory limits, including COD at 129 mg/L against a limit of 500 mg/L and VOCs at 2.29 mg/m³ against a limit of 60 mg/m³[83][84]. - The company has received recognition for its environmental efforts, including being rated as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for 2021[90]. - The company emphasizes its commitment to social responsibility and actively supports education and scientific research in China[93]. - The company donated 3 million RMB to Chengdu University of Traditional Chinese Medicine for the "Double First-Class" initiative in October 2021, ensuring effective use of funds for talent cultivation and technology research[93]. Acquisitions and Investments - The company acquired 100% equity in Sichuan Blue Light Mineral Water Co., Ltd. for 61,000,000.00 yuan, effective January 1, 2022[55]. - The company also acquired 100% equity in Chengdu Yuanhong Mineral Water Co., Ltd. for 33,200,000.00 yuan, effective June 30, 2022[55]. - The company reported an investment amount of 108,200,000.00 yuan for the reporting period, a significant increase of 9,362.32% compared to 1,143,483.00 yuan in the same period last year[53]. Risks and Challenges - The company has identified risks related to drug price reductions due to government policies, which could adversely affect sales and overall operations[69]. - The company emphasizes a cautious approach to new business development, prioritizing risk control and market demand alignment[74].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 206,595,617.51, representing a 39.11% increase compared to CNY 148,511,424.02 in the same period last year[3]. - The net profit attributable to shareholders decreased by 19.48% to CNY 9,433,788.66 from CNY 11,715,714.45 year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 33.59% to CNY 9,230,154.56, down from CNY 13,899,723.69[3]. - The net profit for the first quarter was CNY 8,621,028.17, compared to CNY 11,865,391.51 in the same period last year, reflecting a decrease of approximately 27%[18]. - The basic and diluted earnings per share were both CNY 0.0151, compared to CNY 0.0187 in the previous period, indicating a decrease of 19.3%[19]. - The total comprehensive income attributable to the parent company was CNY 9,433,788.66, down from CNY 11,715,714.45, reflecting a decline of 19.5%[19]. Cash Flow - The net cash flow from operating activities increased by 134.17% to CNY 19,660,473.69, compared to a negative cash flow of CNY 57,536,200.29 in the previous year[3]. - Cash inflows from operating activities totaled CNY 223,148,429.87, an increase of 14.1% from CNY 195,544,500.14 in the previous period[21]. - The net cash flow from investing activities was negative CNY 191,086,908.94, worsening from negative CNY 87,370,886.71 in the previous period[21]. - The cash and cash equivalents at the end of the period were CNY 129,570,886.12, down from CNY 234,189,880.71 at the end of the previous period, reflecting a decrease of 44.7%[22]. - The company reported a cash inflow from financing activities of CNY 27,659,959.66, with cash inflows from borrowings amounting to CNY 28,020,000.00[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,406,259,884.96, a 7.57% increase from CNY 1,307,282,000.53 at the end of the previous year[3]. - The company’s total liabilities increased to CNY 416,751,257.23 from CNY 327,644,146.36, reflecting a growth of about 27%[16]. - The company’s equity attributable to shareholders rose to CNY 986,261,207.17 from CNY 975,577,673.12, an increase of approximately 1.3%[16]. Research and Development - The company reported a significant increase in R&D expenses by 245.61%, amounting to CNY 506.92 million, due to increased investment in research and development[8]. - The company reported a significant increase in research and development expenses, which rose to CNY 7,133,097.95 from CNY 2,063,937.22, marking an increase of about 246%[18]. Expenses - The total operating costs amounted to CNY 196,927,814.86, up from CNY 130,601,415.61, indicating a year-over-year increase of about 51%[18]. - The company experienced a 41.40% decrease in selling expenses, totaling CNY 2,366.31 million, attributed to reduced marketing expenditures in the pharmaceutical sector[8]. Investments - The company acquired two subsidiaries, resulting in the recognition of goodwill due to the purchase price exceeding the fair value of identifiable net assets[7]. - The company plans to invest up to CNY 130 million in the construction of a health management center in Haikou, with a property area of approximately 7,960 square meters[12]. Other - The first quarter report was not audited, indicating that the financial figures are subject to further verification[23].

Financial Performance - The company's operating revenue for 2021 was CNY 945,317,490.17, representing a 24.50% increase compared to CNY 759,307,481.01 in 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 70,321,594.57, an increase of 87.51% from CNY 37,503,531.51 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 70,286,853.72, up 50.08% from CNY 46,834,417.52 in 2020[20]. - The basic earnings per share for 2021 was CNY 0.11, an increase of 83.33% compared to CNY 0.06 in 2020[20]. - The total assets at the end of 2021 were CNY 1,307,282,000.53, a 14.67% increase from CNY 1,140,012,121.38 at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were CNY 975,577,673.12, reflecting a 6.97% increase from CNY 912,050,796.35 in 2020[20]. - The net cash flow from operating activities for 2021 was negative CNY 55,640,088.39, a decrease of 512.28% compared to positive CNY 13,495,800.83 in 2020[20]. - The weighted average return on net assets for 2021 was 7.45%, up from 4.15% in 2020[20]. - The company achieved a total revenue of 945.32 million yuan in 2021, representing a year-on-year growth of 24.50%[52]. - The net profit attributable to shareholders was 70.32 million yuan, an increase of 87.51% year-on-year, while the net profit after deducting non-recurring gains and losses was 70.29 million yuan, up 50.08%[52]. Market Position and Growth - The Chinese pharmaceutical market grew by 12.3% in 2021, with traditional Chinese medicine (TCM) revenue reaching ¥4,862 billion, reflecting a robust growth trend[30]. - The company holds a strong position in the TCM market, with its core product, Sanqi Tongshu Capsule, ranking fourth in sales among oral TCM for cerebrovascular diseases in urban public hospitals[32]. - The company plans to enhance its R&D efforts in new products and technologies to adapt to the evolving pharmaceutical landscape and competitive pressures[30]. - The company aims to enhance its market position by focusing on health and life quality improvement, aligning with the "Healthy China" strategy[45]. - The company is focused on building a comprehensive health management solution to meet the increasing health awareness and consumption demands of the public[92]. - The company aims to establish dual headquarters in Chengdu and Hainan by 2025, focusing on creating a national health industry ecosystem[94]. - The company plans to enhance its pharmaceutical business by optimizing channel resources and expanding clinical and OTC channels[98]. Research and Development - The company holds 105 authorized patents, including 27 invention patents and 4 international patents, showcasing its strong R&D capabilities[47]. - The company completed 30 new patent applications and received 20 authorized patents in 2021, reflecting its commitment to innovation and R&D[54]. - The company emphasizes R&D in traditional Chinese medicine modernization and biomedicine, aiming to accelerate the development of new products and technologies[41]. - The company is focusing on developing new products such as the "Sanqi Tongshu Capsule" and "Biyuan Shuqing Oral Liquid" to enhance market presence and clinical value[72][73]. - Research and development investments increased by 20% in 2021, totaling 100 million yuan, focusing on innovative technologies[123]. Operational Efficiency - The company implemented a performance management system that resulted in a 19.93% increase in employee efficiency compared to 2020[55]. - The company has established a modern Chinese medicine production line that integrates advanced production technologies and real-time quality monitoring, enhancing production efficiency and product quality[48]. - The company has established a sound corporate governance structure in compliance with the requirements of the Company Law and the Guidelines for Corporate Governance of Listed Companies[106]. - The company has implemented strict internal control measures to ensure effective operation and compliance[106]. - The company has established independent financial institutions with a comprehensive accounting system and financial management policies[108]. Risks and Challenges - The company faces potential risks including drug price reductions, COVID-19 impacts, and new product development challenges[5]. - The company faces risks from potential drug price reductions due to regulatory changes and market conditions[102]. - Ongoing COVID-19 pandemic risks may impact hospital operations and project timelines, affecting overall revenue[102]. Corporate Governance and Social Responsibility - The company has established various committees under the board of directors to enhance governance, including a strategy committee and an audit committee[106]. - The company maintains a commitment to timely and accurate information disclosure to support investor decision-making[106]. - The company has been recognized as a "Green Enterprise" by the Sichuan Provincial Department of Ecology and Environment for multiple years, indicating strong environmental compliance[167]. - The company has conducted regular environmental monitoring and audits, with third-party assessments confirming compliance with environmental regulations[166]. - The company emphasizes the protection of shareholder rights by ensuring timely and accurate information disclosure, allowing equal access to information for all shareholders[168]. Employee and Management - The company employed a total of 647 staff members, with 352 in the parent company and 295 in major subsidiaries[134]. - The company has a competitive salary policy to attract and retain talent, with a focus on short, medium, and long-term incentive plans[136]. - The company has implemented a robust employee training program to enhance skills and improve work quality[169]. - The company is focused on strategic growth through the recruitment of experienced executives from various sectors[119]. Future Outlook - The company aims for a net profit of no less than 125% of the 2021 figure for 2022, excluding stock payment expenses due to equity incentives[98]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online sales channels by the end of 2022[121]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by 2025[122]. - The company intends to introduce strategic investors and establish an industrial merger fund to accelerate acquisition speed and reduce market risks[99].

Financial Performance - The company's operating revenue for Q3 2021 was ¥211,495,672.05, a decrease of 4.63% compared to the same period last year[3] - Net profit attributable to shareholders was ¥11,733,667.15, an increase of 41.44% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,012,346.90, down 18.26% from the previous year[3] - Basic earnings per share for the period were ¥0.0190, up 40.74% compared to the same period last year[3] - Total operating revenue for Q3 2021 was CNY 546,420,942.10, an increase from CNY 534,031,162.03 in the previous period[22] - Net profit for Q3 2021 reached CNY 38,976,010.50, up from CNY 30,846,841.36 in the same period last year, representing a growth of approximately 26.5%[23] - The company reported a basic earnings per share of CNY 0.0631, compared to CNY 0.0500 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,231,892,652.77, reflecting an increase of 8.06% from the end of the previous year[4] - The company's total assets increased to CNY 1,231,892,652.77 from CNY 1,140,012,121.38 year-over-year[20] - Total liabilities rose to CNY 285,626,725.86, compared to CNY 227,558,599.33 in the previous period[20] - The total non-current assets amounted to CNY 381,417,275.53, an increase from CNY 273,950,052.58 year-over-year[20] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥65,569,615.26, a significant decline of 841.83% year-to-date[3] - The company's cash flow from operating activities was CNY 499,877,777.94, down from CNY 518,732,406.74 in the previous period[26] - The net cash flow from operating activities was -65,569,615.26 CNY, compared to -6,961,921.94 CNY in the previous year, indicating a significant decline[27] - Total cash inflow from operating activities amounted to 535,412,335.10 CNY, while cash outflow was 600,981,950.36 CNY, resulting in a net cash outflow of 65,569,615.26 CNY[27] - Cash flow from investment activities showed a net outflow of -96,156,587.60 CNY, compared to -29,509,688.98 CNY in the same period last year[28] - The company received 16,000,000.00 CNY from financing activities, with a net cash inflow of 9,102,167.16 CNY after accounting for outflows[28] Expenses - The company’s management expenses increased by 34.38% to ¥39,872,019.71, mainly due to costs associated with the health industry project[11] - The company’s financial expenses decreased by 65.49% to -¥2,025,443.04, attributed to a reduction in bank deposits leading to lower interest income[11] - Research and development expenses for Q3 2021 were CNY 13,535,458.12, a decrease from CNY 18,160,280.09 in the previous period[23] - Cash paid for purchasing goods and services increased by 45.38% to CNY 280,983,278.43, due to preemptive stockpiling in response to rising raw material prices[12] - The company paid 65,620,900.58 CNY to employees, an increase from 53,600,183.60 CNY in the previous year[27] Shareholder Information - The company’s major shareholder, Sichuan Huasheng Group, holds 18.08% of shares, with 89,033,593 shares pledged[14] - The company terminated its non-public offering of A-shares, which was pending approval from the China Securities Regulatory Commission[16] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 641.59% to ¥49,330,777.54, primarily due to advance payments for steel structure project materials[8] - Investment income increased by 100.41% to CNY 899,729.08, primarily due to the recognition of investment losses from the previous year[12] - Credit impairment losses rose by 153.46% to CNY 3,286,671.55, mainly due to the recovery of receivables[12] - Total current assets decreased to CNY 850,475,377.24 from CNY 866,062,068.80, indicating a decline in liquidity[18] - Cash and cash equivalents decreased to CNY 253,630,835.90 from CNY 405,151,171.60, showing a significant reduction in cash reserves[18] - Inventory increased to CNY 97,415,329.00 from CNY 75,842,157.21, indicating a buildup of stock[18] - The company did not undergo an audit for the third quarter report[29] - The company has not applied the new leasing standards for the financial statements[29]

证券代码：000790 证券简称：华神科技 公告编号：2021-073 成都华神科技集团股份有限公司 关于参加2021年四川辖区上市公司 投资者集体接待日的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 为便于广大投资者更深入全面地了解公司情况，就公司治理及社会责任 /ESG、经营状况、发展战略、风险防控、市值管理、投资者保护等投资者所关 心的问题，公司定于 2021 年 9 月 16 日 15:00-17:00 参加由四川省上市公司协会 联合深圳市全景网络有限公司举办的主题为"守初心担使命 为投资者办实 事"2021 年四川辖区上市公司投资者网上集体接待日活动。现将有关事项公告如 下： 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.net 进入专区 页面参与交流。 出席本次集体接待日的人员有：公司董事长、总裁黄明良先生；财务总监李 俊先生；董事会秘书刁海雷先生。 欢迎广大投资者积极参与。 特此公告。 成都华神科技集团股份有限公司 董事会 二〇二一年九月十四日 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥334,925,270.05, representing a 7.25% increase compared to ¥312,273,442.44 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was ¥27,170,249.27, a 20.48% increase from ¥22,550,767.77 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥32,227,215.21, reflecting a 24.89% increase from ¥25,803,802.83 year-on-year[21]. - The basic earnings per share for the first half of 2021 was ¥0.0441, up 20.49% from ¥0.0366 in the same period last year[21]. - The total operating revenue for the reporting period was CNY 334,925,270.05, representing a year-on-year increase of 7.25% compared to CNY 312,273,442.44 in the same period last year[41]. - The company reported a total profit of ¥31,647,913.10 for the first half of 2021, compared to ¥25,483,827.24 in the first half of 2020, representing an increase of approximately 24.5%[135]. - The company reported a net profit increase, with retained earnings rising to CNY 159,761,577.21 from CNY 138,754,933.58, an increase of approximately 15.1%[127]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,178,038,023.04, a 3.34% increase from ¥1,140,012,121.38 at the end of the previous year[21]. - The total liabilities increased to CNY 243,423,613.31 from CNY 227,558,599.33, representing a rise of about 6.9%[127]. - The company's total equity reached CNY 934,614,409.73, up from CNY 912,453,522.05, indicating an increase of approximately 2.0%[127]. - The company's cash and cash equivalents decreased significantly to CNY 129,195,348.83 from CNY 269,702,162.44, a decline of about 52.0%[129]. - The company's accounts receivable stood at CNY 239,448,582.32, representing 20.33% of total assets, down 1.59% from the previous year[47]. - The company's inventory was valued at CNY 65,374,083.39, which is a decrease of 1.10% from CNY 75,842,157.21 in the previous year[47]. Cash Flow - The net cash flow from operating activities was negative at -¥46,328,881.46, a decline of 173.13% compared to -¥16,962,117.57 in the same period last year[21]. - The cash flow from investment activities showed a net outflow of -CNY 95,433,434.42, compared to a net inflow of CNY 3,822,523.79 in the first half of 2020[145]. - The total cash outflow from operating activities reached CNY 409,991,732.70, up 13.8% from CNY 360,336,938.61 in the previous year[144]. - The cash outflow for purchasing goods and services was CNY 171,456,507.89, which is a significant increase from CNY 126,281,336.32 in the first half of 2020[142]. Business Segments - The pharmaceutical manufacturing segment generated revenue of 245,448,400 CNY, a slight decrease of 2.73% year-on-year due to domestic medical insurance cost control and centralized procurement policies[33]. - The construction steel structure business saw revenue increase by 54.96% year-on-year, reaching 84,502,600 CNY, driven by enhanced market expansion and project implementation[33]. - The pharmaceutical manufacturing sector generated CNY 245,448,353.80, accounting for 73.28% of total revenue, but saw a decline of 2.73% from CNY 252,333,096.27[41]. Research and Development - The company obtained 13 authorized patents during the reporting period, enhancing its research and development capabilities[31]. - The company plans to enhance its research and development efforts, focusing on modern traditional Chinese medicine and biotechnology, to drive product innovation and market expansion[62]. - Research and development expenses rose to ¥9,818,160.05 in the first half of 2021, compared to ¥7,400,455.98 in the first half of 2020, an increase of approximately 32.5%[134]. Environmental Compliance - The company has been recognized as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for three consecutive years (2018-2020)[77]. - The company has a complete wastewater treatment system and a corresponding exhaust gas treatment system, ensuring compliance with environmental standards[72]. - The company has established an emergency response plan for environmental incidents and conducts regular drills[74]. Corporate Governance - The company held three shareholder meetings during the reporting period, with investor participation rates of 25.51%, 18.95%, and 19.92% respectively[65]. - The company has appointed new executives, including a new Chief Financial Officer and Executive Vice President, during the reporting period[66]. - The financial report was approved by the board of directors on August 27, 2021[175]. Future Outlook - The company plans to continue expanding its market presence and invest in new technologies[159]. - The company is in the process of a non-public offering of A-shares, pending approval from the China Securities Regulatory Commission[104].